Impact of depressive symptoms on subjective well-being: The importance of patient-reported outcomes in schizophrenia

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 471-474

  Mauriño, Jorge ^a   Sanjúan, Julio ^b   Haro, Josep Maria ^c   Díez, Teresa ^a   Ballesteros, Javier ^d  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Depressive symptoms; Patient reported outcome; Schizophrenia; Subjective well being

Indexed keywords

ADULT; ARTICLE; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; EMOTIONALITY; FEMALE; HUMAN; INTEGRATION; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHYSICAL CAPACITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGICAL WELL BEING; SCHIZOPHRENIA; SELF CONTROL; SELF REPORT; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC SCALE;

EID: 84857094459     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S24479     Document Type: Article

References (25)

1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.
2. McCabe R, Saidi M, Priebe S. Patient-reported outcomes in schizophrenia. Br J Psychiatry Suppl. 2007;191(50):S21-S28.
3. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
4. Marder S. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl. 2005;427:43-46.
5. Singh MM, Kay SR. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol Psychiatry. 1979;14:277-294.
6. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
7. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19:609-618.
8. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
9. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10 Suppl 3:133-138.
10. Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res. 2000;45:223-234.
11. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-247.
12. Voruganti L, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37-46.
13. Barberá M, Sanjuán J, Munárriz M, Novella E, Santiago C, Simó M. Subjective experience with antipsychotics:quantitative evaluation. Actas Esp Psiquiatr. 2006;34:287-294. Spanish.
14. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
15. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2011; Epub May 27, 2011.
16. Schennach-Wolff R, Obermeier M, Seemüller F, et al. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand. 2011; 123:228-238.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition; Text Revision. Washington, DC: American Psychiatric Association, 2000.
18. Sanjúan J, Haro JM, Mauriño J, Díez T, Ballesteros J. Validation of the Spanish version of the Subjective Well-being under Neuroleptic Scale (SWN-K) in patients with schizophrenia. Med Clin (Barc). 2011; Epub May 13, 2011.
19. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201-208.
20. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Margariti MM, Collias CT, Christodoulou GN. Comparison of four scales measuring depression in schizophrenic inpatients. Eur Psychiatry. 2000;15: 274-277.
21. Sarró S, Dueñas RM, Ramírez N, et al. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophr Res. 2004;68:349-356.
22. Burns T. Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl. 2007;191:S1-S6.
23. US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.
24. Kim JH, Ann JH, Kim MJ. Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. J Clin Pharm Ther. 2011;36:172-178.
25. Hunter R, Cameron R, Norrie J. Using patient-reported outcomes in schizophrenia: The Scottish schizophrenia outcomes study. Psychiatr Serv. 2009;60:240-245.